Alembic Pharmaceuticals receives USFDA tentative approval for generic Bosutinib tablets, a cancer treatment drug. ANDA ...

The leading Chronic Myeloid Leukemia Companies such as Kartos Therapeutics, AOP Orphan Pharmaceuticals, Biokine Therapeutics, ...

Alembic Pharmaceuticals Ltd has obtained tentative approval from the USFDA for its Bosutinib tablets, used to treat specific ...

Alembic Pharmaceuticals secures USFDA tentative approval for 400 mg Bosutinib tablets, a generic cancer treatment option.

Bosutinib is a kinase inhibitor used in the treatment of adult patients with Philadelphia chromosome-positive chronic ...

Chronic myeloid leukemia highlights from ASH 2025 include data on nilotinib vs imatinib, asciminib in second line, somatic mutations and imatinib failure, and dasatinib with a switch to imatinib.

The pharma business also announced that it has already secured final USFDA approvals for Bosutinib Tablets in the 100 mg and ...

Modern medical breakthroughs save lives in ways that feel miraculous, showing how faith and science can work together as ...

Alembic Pharmaceuticals Limited (Alembic) has announced that it has received tentative approval from the US Food & Drug ...

Bosutinib Tablets, 400 mg, had an estimated market size of $251 million for the twelve months ended September 2025, ...

Novel next-generation Bruton tyrosine kinase (BTK)-targeted protein degrader APG-3288 has received investigational new drug ...

Enliven Therapeutics (EVN) stock jumps as the company post initial early-stage trial data for its lead asset ELVN-001 in ...